Cardiology, Diabetes & Nephrology at the Limits 2017: Multimedia

Please click on the presentation title to view the multimedia, or click on the speaker name to view their bio.

Saturday morning

09.15
Dr Peter Libby
The Lancet Lecture:
Novel concepts of the pathogenesis of the acute coronary syndromes.
Dr Peter Libby
Harvard Medical School, Boston, USA

10.00
Dr Alex Lyon
Cardio-Oncology – preventing the cancer patient of today being the heart failure patient of tomorrow!
Dr Daniel Lenihan
Vanderbilt University Medical Center, Nashville, USA

11.10
Professor Natan Bornstein
What is the connection between the heart and the brain?
Professor Natan Bornstein
Tel Aviv Medical Centre, Israel

11.50
Professor Bernard Gersh
PCI vs CABG for multi-vessel and left main coronary disease – do we have the evidence?
Professor Bernard Gersh
Mayo Clinic College of Medicine, Rochester, USA

Saturday afternoon

13.30
Professor C Noel Bairey Merz
The Hatter Award Lecture:
Is it time to look at microvascular angina? Are these the new limits?
Dr C Noel Bairey Merz
Cedars-Sinai Heart Institute, California, USA

14.10
Professor John Wilding
SGLT2 inhibition – a novel strategy to improve type 2 diabetes, cardiovascular & renal outcome
Professor John Wilding
University Hospital, Liverpool, UK

14.50
Professor Steven Weisbord
Trials and tribulations in AKI. Do we know where we are going?
Dr Steven Weisbord
VA Pittsburgh Healthcare System, USA

16.00
Professor Gerd Heusch
The preconditioning phenomenon – lost in translation?
Professor Gerd Heusch
University of Essen, Germany

16.40
Professor David Wheeler
The NIHR-UCLH Biomedical Research Centre Lecture:
Diabetes & the kidney: BP control-how low can you go?
Professor David Wheeler
University College London, UK

Sunday morning

09:00
Professor Naomi Levitt
The global burden of diabetes.
Professor Naomi Levitt
University of Cape Town, South Africa

09:40
Dr Liesl Zuhlke
The SA Heart & British Cardiovascular Society Lecture:
The prevention, management and control of rheumatic heart disease: are we at the limits?
Professor Liesl Zühlke
University of Cape Town, South Africa

10:50
Professor Chris Winearls
eGFR & CKD Staging. Better understanding or a struggle with the law of unintended consequences?
Dr Chris Winearls
University of Oxford, UK

11:30
Professor Allison Goldfine
GLP-1 analogues & DPPIV Inhibitors – are there new limits for beneficial cardiovascular outcome in type 2 diabetes?
Professor Allison Goldfine
Joslin Diabetes Centre, Boston, USA

Sunday afternoon

13:10
Professor Kausik Ray
PCSK9 inhibition – have we reached the limits of lipid lowering and outcome?
Professor Kausik Ray
Imperial College, London, UK

13:50
Professor Iain MacDougall v Dr Marc Pfeffer
Debate: Strategies for optimising haemoglobin in CKD (both pre and post dialysis) & CV Disease. What level and how to get there?
For: Professor Iain Macdougall
Kings College, London, UK

 

Against: Dr Marc Pfeffer
Harvard University, Boston, USA